Reset filter
Keywords
Psychiatry ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

816 Search results.
Relevance Rating New first Old first

WHO-5 - WHO (Five) Well-Being Index

- 12/13/24 - 1 form, 1 itemgroup, 5 items, 30 languages
Itemgroup: Over the last two weeks
WHO (Five) Well-Being Index (1998 version) Also called : WHO Five, WHO 5 [Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167-76. doi: 10.1159/000376585]

Hamilton Depression Rating Scale - F.1

- 4/11/22 - 1 form, 1 itemgroup, 19 items, 2 languages
Itemgroup: IG.1
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62 CIPS(1977) Rating: Clinician-rated Administration time: 20–30 minutes Main purpose: To assess severity of, and change in, depressive symptoms Population: Adults

The relationship of Glycine Transporter1 occupancy by GSK1018921 to plasma concentrations over time NCT00945503 - Day 1 - Vital Signs; 12-Lead ECG; Laboratory Results Data (Haematology, Clinical Chemistry) - Pre-Dose and 24h Post-Dose; Urinalysis - Pre-Dose and 24h Post-Dose; Randomisation Number; Investigational Product; Treatment Confirmation; PET Scan (2); fMRI Scan - Post-PET Scan; PET Scan (3); Pharmacokinetics - Blood

- 4/6/22 - 1 form, 16 itemgroups, 158 items, 1 language
Itemgroups: Administrative, Vital Signs, 12-Lead ECG, Laboratory Results Data (Haematology) - Pre-Dose, Laboratory Results Data (Clinical Chemistry) - Pre-Dose, Urinalysis - Pre-Dose, Randomisation Number, Investigational Product, Treatment Confirmation, PET Scan (2), fMRI Scan - Post-PET Scan, PET Scan (3), Pharmacokinetics - Blood, Laboratory Results Data (Haematology) - 24hrs Post-Dose, Laboratory Result Data (Clinical Chemistry) - 24hrs Post-Dose, Urinalysis - 24hrs Post-Dose
Study ID: 109731 Clinical Study ID: 109731 Study Title: An adaptive PET study in healthy volunteers using 11C GSK931145 to establish the relationship of Glycine Transporter1 occupancy by GSK1018921 to plasma concentrations over time Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00945503 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK1018921 Study Indication: Schizophrenia

Borderline Personality Disorder Severity Index (Version IV) - deutsche Fassung - BPDSI-IV

- 3/31/22 - 1 form, 9 itemgroups, 72 items, 1 language
Itemgroups: Verlassenwerden, Zwischenmenschliche Beziehungen, Identität, Impulsivität, Parasuizidales Verhalten, Affektive Instabilität, Gefühl der Leere, Wutausbrüche, Dissoziation und paranoide Vorstellungen
Angepasst nach: https://www.testarchiv.eu/de/test/9007150 Bitte um Rückmeldung über die Anwendung eines Verfahrens aus dem Testarchiv des Leibniz-Instituts für Psychologie (ZPID) via deren Homepage an die Testautoren/-innen. Der aus dem Amerikanischen ins Holländische und dann ins Deutsche übersetzte BPDSI-IV ist ein semistrukturiertes, klinisches Interviewverfahren, welches spezifische BPS-Symptome der letzten drei Monate erfasst. Er erfasst in seiner 70-Itemfassung analog zu den DSM-IV-Kriterien die neun Symptombereiche (1) Verlassen werden, (2) Zwischenmenschliche Beziehungen, (3) Identität, (4) Impulsivität, (5) Parasuizidales Verhalten, (6) Affektive Instabilität, (7) Gefühl der Leere, (8) Wutausbrüche und (9) Dissoziation und paranoide Vorstellungen. Reliabilität: Die interne Konsistenz liegt über Alpha = .90 (Gesamtscore) bzw. zwischen Alpha = .49 und .89 (Skalen). Iteminterkorrelationen der Gesamtgruppe fallen höher aus mit r = .33 bis .73 als die der BPS-Patienten (r = .22-.52). Validität: Es konnten hohe Korrelationen mit ähnlichen Instrumenten (MSI-BPD, SKID-II) und einzelnen Skalen von verschiedenen Selbstbeurteilungsverfahren (z. B. BDI, BSI, FDS), Unterschiede zwischen den erreichten Mittelwerten (BPS Achse-I-Störung ohne Störung) sowie die Veränderungssensitivität nachgewiesen werden. Die Eindimensionalität des Verfahrens konnte nicht bestätigt werden. Berechnungen der Skaleninterkorrelation fielen heterogen aus. Das Verfahren weist eine Sensitivität von 94 % und eine Spezifität von 93 % auf. Normen: Es liegen Cut-off-Werte vor. Zitierung Kröger, C., Vonau, M., Kliem, S., Roepke, S., Kosfelder, J. & Arntz, A. (2016). BPDSI-IV. Borderline Personality Disorder Severity Index (Version IV) - deutsche Fassung [Verfahrensdokumentation, Interviewleitfaden deutsch und englisch, Bewertungsbogen]. In Leibniz-Institut für Psychologie (ZPID) (Hrsg.), Open Test Archive. Trier: ZPID. https://doi.org/10.23668/psycharchives.4532

Risk perception and optimism during the early stages of the COVID-19 pandemic - Questionnaire risk perception and optimism about COVID-19

- 1/5/22 - 1 form, 7 itemgroups, 151 items, 1 language
Itemgroups: Risk perception for COVID-19, Control questions for optimism, Adherence to protective measures, Mental health, General control questions, Other, Demographics
In this study, we assessed risk perception and optimism about COVID-19 in a multinational (UK, USA and Germany), longitudinal design during the early stages of the pandemic (16 March 2020; 1 April 2020; 20 May 2020). Our main findings are that (i) people showed a comparative optimism bias about getting infected and infecting others, but not for getting severe symptoms, (ii) this optimism bias did not change over time, (iii) optimism bias seemed to relate to perceived level of control over the action, (iv) risk perception was linked to publicly available information about the disorder, (v) people reported adhering closely to protective measures but these measures did not seem to be related to risk perception, and (vi) risk perception was related to questions about stress and anxiety. Kuper-Smith BJ, Doppelhofer LM, Oganian Y, Rosenblau G, Korn CW. 2021 Risk perception and optimism during the early stages of the COVID-19 pandemic. R. Soc. Open Sci. 8: 210904. https://doi.org/10.1098/rsos.210904

Eligibility Schizophrenia and Disorders With Psychotic Features NCT00791882

- 9/28/21 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Social Skills Training in Refractory Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00791882

Effect of Lamictal on Resting Motor Threshold Study-ID 107434 - ECG Abnormalities Form

- 9/27/21 - 1 form, 8 itemgroups, 98 items, 1 language
Itemgroups: Administrative Data, ECG Abnormalities, Rhythm, P-Wave and QRS Morphology, Conduction, Myocardial Infarction, Depolarisation/Repolarisation (QRS-T), Other Abnormalities
Study ID: 107434 Clinical Study ID: NAP107434 Study Title: A randomised, double-blind, double-dummy, placebo controlled, three-way cross-over study to investigate the effect of single oral doses of 100 mg GW273225 (4030W92) and 325 mg LAMICTAL on resting motor threshold in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Study Link: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GW273225 Trade Name: lamictal Study Indication: Bipolar Disorder This form contains information about any recorded ECG abnormalities during the study. It should be filled out everytime an ECG is performed.

Eligibility Postpartum Depression NCT00744328

- 9/20/21 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Postpartum Depression: Transdermal Estradiol Versus Sertraline; ODM derived from: https://clinicaltrials.gov/show/NCT00744328

Emotional processing in healthy male volunteers treated with GSK424887 NCT01424384 - Logs and Repeats and Concomitant Medications

- 9/20/21 - 1 form, 3 itemgroups, 23 items, 1 language
Itemgroups: Date of visit/ assessment, Adverse event | Concomitant Medication Ongoing | Evaluation, Pharmaceutical Preparations Concomitant Therapy
Study ID: 105012 Clinical Study ID: NSS105012 Study Title: Emotional processing in healthy male volunteers treated with GSK424887. A single centre, randomised, double-blind, placebo-controlled parallel group study Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01424384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK424887 Trade Name: Citalopram Study Indication: Depressive Disorder and Anxiety Disorders

Emotional processing in healthy male volunteers treated with GSK424887 NCT01424384 - Repeat Local laboratory, urinalysis, vital signs, ECG and Pharmacokinetics

- 9/20/21 - 1 form, 8 itemgroups, 58 items, 1 language
Itemgroups: Local Laboratory, Urinalysis | Local, Vital signs, 12 lead ECG, Electrocardiogram abnormal, Drug Kinetics; Blood, 12 lead ECG | Holter Electrocardiography | Summary Report, Holter Electrocardiography | Electrocardiogram abnormal | Summary Report
Study ID: 105012 Clinical Study ID: NSS105012 Study Title: Emotional processing in healthy male volunteers treated with GSK424887. A single centre, randomised, double-blind, placebo-controlled parallel group study Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01424384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK424887 Trade Name: Citalopram

Emotional processing in healthy male volunteers treated with GSK424887 NCT01424384 - Vital Signs and ECG - Screening

- 9/20/21 - 1 form, 5 itemgroups, 28 items, 1 language
Itemgroups: Patient identification, Vital signs, 12 lead ECG, Holter Electrocardiography | Summary Report, Holter Electrocardiography | Electrocardiogram abnormal | Summary Report
Study ID: 105012 Clinical Study ID: NSS105012 Study Title: Emotional processing in healthy male volunteers treated with GSK424887. A single centre, randomised, double-blind, placebo-controlled parallel group study Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01424384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK424887 Trade Name: Citalopram Study Indication: Depressive Disorder and Anxiety Disorders

Eligibility Major Depressive Disorder NCT00785434

- 9/20/21 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD; ODM derived from: https://clinicaltrials.gov/show/NCT00785434

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial